PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26026F0076BULK - arcalyst 220mg VIL — Kiniksa Pharmaceuticals (Uk), Ltd

Kiniksa Pharmaceuticals (Uk), Ltd holds $1.2M across 22 federal awards, concentrated at Department of Veterans Affairs (VA). The prior award was single-bid — competitive dynamics may favor a challenge. Recompete timing centers on the Dec 14, 2026 PoP end — agencies typically plan 12–18 months ahead.

260-Network Contract Office 20 (36C260)

Awarding office

Kiniksa Pharmaceuticals (Uk), Ltd

Recipient

Dec 14, 2026

PoP end

$220K

Obligated

$220K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Kiniksa Pharmaceuticals (Uk), Ltd — $90

Contract facts

Federal

Contract number36C26026F0076

Also listed as36C260-26-F-0076

Also listed as36F79722D0002-36C26026F0076

Agency260-Network Contract Office 20 (36C260)

Awarding office260-Network Contract Office 20 (36C260)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentKiniksa Pharmaceuticals (Uk), Ltd

CAGEU1S38

UEIHBHWNLNMHSV5

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79722D0002

Place of performanceDUBLIN OH

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startDec 15, 2025

PoP end (current)Dec 14, 2026

Obligated$220K

Current value$220K

Potential value$220K

BULK - ARCALYST 220MG VIL is a federal award for 260-Network Contract Office 20 (36C260) held by Kiniksa Pharmaceuticals (Uk), Ltd. Estimated value $220K ($220K obligated). Current period of performance ends Dec 14, 2026. Last award drew 1 bidder. Place of performance: DUBLIN OH.

Recompete timing

Public

● Expiring in 115 days

Current PoP ends Dec 14, 2026 (115 days remaining). Agencies typically plan 12–18 months ahead — at 3.8 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Kiniksa Pharmaceuticals (Uk), Ltd — $1.2M obligated across 22 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($1.2M) · all agencies

Department of Veterans Affairs (VA)$942K · 79%Department of Justice (DOJ)$269K · 22%

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26026F0076?

36C26026F0076 (BULK - arcalyst 220mg VIL) is a 260-Network Contract Office 20 (36C260) award with a potential value of $220K, currently held by Kiniksa Pharmaceuticals (Uk), Ltd. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C260-26-F-0076?

36C260-26-F-0076 is the dashed form of PIID 36C26026F0076 (BULK - arcalyst 220mg VIL), held by Kiniksa Pharmaceuticals (Uk), Ltd. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26026F0076?

260-Network Contract Office 20 (36C260) awarded 36C26026F0076 to Kiniksa Pharmaceuticals (Uk), Ltd (potential $220K).

Who is the incumbent on 36C26026F0076?

Kiniksa Pharmaceuticals (Uk), Ltd is the incumbent with $1.2M across 22 related awards in SCOUT’s public footprint. The current period of performance ends Dec 14, 2026.

When does Kiniksa Pharmaceuticals (Uk), Ltd’s 36C26026F0076 come up for recompete?

SCOUT tracks a period-of-performance end of Dec 14, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Feb 18, 2026